Drug shortage concerns with select angiotensin receptor blockers (ARBs) (i.e., valsartan) and early concerns that angiotensin-converting enzyme inhibitors and ARBs could potentially worsen COVID-19 patient outcomes should be noted. This evidence concerns the gene ACE and COVID-19.